newsfilter
← Latest News
GlobeNewswire·

Immunovant Announces Pricing of $550 Million Common Stock Financing

Funding to provide runway through potential Graves' Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling